Comparative Pharmacology
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus IBUPROFEN LYSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus IBUPROFEN LYSINE.
ADVIL CONGESTION RELIEF vs IBUPROFEN LYSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Ibuprofen lysine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
200-800 mg orally every 6-8 hours as needed; maximum 2400 mg/day. Intravenous: 400-800 mg every 6 hours; maximum 3.2 g/day.
None Documented
None Documented
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
2–4 hours in adults; extended to 4–6 hours in neonates. In severe hepatic or renal impairment, half-life may increase up to 8–10 hours.
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Renal excretion of metabolites and conjugates accounts for >90% of elimination; less than 1% is excreted unchanged in urine. Fecal excretion is minimal (<5%).
Category C
Category D/X
NSAID/Decongestant Combination
NSAID